Similar articles for PMID: 21709111

Year	Number of Results
2001	1
2002	1
2004	3
2005	6
2006	7
2007	6
2008	13
2009	12
2010	5
2011	8
2012	4
2013	4
2014	6
2015	3
2016	6
2017	8
2021	1
2022	2
2023	1
2024	0

1

Study of neurontin: titrate to effect, profile of safety (STEPS) trial: a narrative account of a gabapentin seeding trial.

Krumholz SD, Egilman DS, Ross JS. Krumholz SD, et al. Arch Intern Med. 2011 Jun 27;171(12):1100-7. doi: 10.1001/archinternmed.2011.241. Arch Intern Med. 2011. PMID: 21709111 Free PMC article.

2

Implementation of a publication strategy in the context of reporting biases. A case study based on new documents from Neurontin litigation.

Vedula SS, Goldman PS, Rona IJ, Greene TM, Dickersin K. Vedula SS, et al. Trials. 2012 Aug 13;13:136. doi: 10.1186/1745-6215-13-136. Trials. 2012. PMID: 22888801 Free PMC article.

3

The ADVANTAGE seeding trial: a review of internal documents.

Hill KP, Ross JS, Egilman DS, Krumholz HM. Hill KP, et al. Ann Intern Med. 2008 Aug 19;149(4):251-8. doi: 10.7326/0003-4819-149-4-200808190-00006. Ann Intern Med. 2008. PMID: 18711155 Free article. Review.

4

Narrative review: the promotion of gabapentin: an analysis of internal industry documents.

Steinman MA, Bero LA, Chren MM, Landefeld CS. Steinman MA, et al. Ann Intern Med. 2006 Aug 15;145(4):284-93. doi: 10.7326/0003-4819-145-4-200608150-00008. Ann Intern Med. 2006. PMID: 16908919 Free article. Review.

5

Differences in reporting of analyses in internal company documents versus published trial reports: comparisons in industry-sponsored trials in off-label uses of gabapentin.

Vedula SS, Li T, Dickersin K. Vedula SS, et al. PLoS Med. 2013;10(1):e1001378. doi: 10.1371/journal.pmed.1001378. Epub 2013 Jan 29. PLoS Med. 2013. PMID: 23382656 Free PMC article.

6

Evidence, regulation and 'rational' prescribing: the case of gabapentin for neuropathic pain.

Ghinea N, Lipworth W, Kerridge I. Ghinea N, et al. J Eval Clin Pract. 2015 Feb;21(1):28-33. doi: 10.1111/jep.12223. Epub 2014 Jul 2. J Eval Clin Pract. 2015. PMID: 24986307

7

Seeding trials and the subordination of science.

Alexander GC. Alexander GC. Arch Intern Med. 2011 Jun 27;171(12):1107-8. doi: 10.1001/archinternmed.2011.232. Arch Intern Med. 2011. PMID: 21709112 No abstract available.

8

Outcome reporting in industry-sponsored trials of gabapentin for off-label use.

Vedula SS, Bero L, Scherer RW, Dickersin K. Vedula SS, et al. N Engl J Med. 2009 Nov 12;361(20):1963-71. doi: 10.1056/NEJMsa0906126. N Engl J Med. 2009. PMID: 19907043 Free article.

9

The rise and fall of gabapentin for bipolar disorder: a case study on off-label pharmaceutical diffusion.

Fullerton CA, Busch AB, Frank RG. Fullerton CA, et al. Med Care. 2010 Apr;48(4):372-9. doi: 10.1097/MLR.0b013e3181ca404e. Med Care. 2010. PMID: 20195173 Free PMC article.

10

False Claims Act prosecution did not deter off-label drug use in the case of neurontin.

Kesselheim AS, Darby D, Studdert DM, Glynn R, Levin R, Avorn J. Kesselheim AS, et al. Health Aff (Millwood). 2011 Dec;30(12):2318-27. doi: 10.1377/hlthaff.2011.0370. Health Aff (Millwood). 2011. PMID: 22147859

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

93 results

Results by year